Anti-androgen monotherapy versus gonadotropin-releasing hormone agonists in men with advanced, non-metastatic prostate cancer: a register-based, observational study.
CONCLUSION: Our results indicate that the use of AA as primary hormonal therapy in men with high-risk non-metastatic PCa does not increase PCa-specific mortality compared to GnRH. Using AA instead of GnRH agonists may result in shorter time on/exposure to GnRH-treatment, which may reduce the risk of adverse events associated with this treatment.
PMID: 30375907 [PubMed - as supplied by publisher]
Source: Acta Oncologica - Category: Cancer & Oncology Authors: Thomsen FB, Bosco C, Garmo H, Adolfsson J, Hammar N, Stattin P, Van Hemelrijck M Tags: Acta Oncol Source Type: research
More News: Cancer | Cancer & Oncology | Hormonal Therapy | Hormones | Prostate Cancer | Study | Sweden Health